Tags:DevelopmentDrugTechnologyTime
NexMR aims to deliver fully characterized hits to support drug discovery pipelines. Thanks to our proprietary technology using sensitivity-enhanced NMR we can screen libraries of thousands of molecules within days. We are also able to characterize the hits without idle time, as our technology encompasses affinity and structure determination. Contrary to state-of-the-art methods (X-ray crystallography, surface plasmon resonance), we only require minimal assay development, allowing us to screen challenging targets which were not addressed so far. The sample conditions used in NMR are milder and closer to physiological conditions than for other techniques, therefore facilitating the transition to further development.

Investors 1

DateNameWebsite
03.05.2022Venture Ki...venturekic...

Mentions in press and media 2

DateTitleDescriptionCategoryAuthorSource
15.06.2022CHF 40,000...NexMR: NMR-based fragment scre...--venturekic...
30.03.2022Startups d...MinWave Technologies: Microwav...--venturekic...